Хайлтын үр дүнгүүд - Hiromichi Ebi

Үр дүнг сайжруулах
  1. 1
    Precision Oncology and the Universal Health Coverage System in Japan

    Precision Oncology and the Universal Health Coverage System in Japan -н Hiromichi Ebi, Hideaki Bando

    Хэвлэсэн 2019
    Бүрэн текст авах
    Revisão
    Жагсаалт руу хадгалах
    -д хадгалсан:
  2. 2
    Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer

    Epithelial-to-Mesenchymal Transition is a Cause of Both Intrinsic and Acquired Resistance to KRAS G12C Inhibitor in KRAS G12C–Mutant Non–Small Cell Lung Cancer -н Yuta Adachi, Kentaro Ito, Yuko Hayashi, Ryo Kimura, Tuan Zea Tan, Rui Yamaguchi, Hiromichi Ebi

    Хэвлэсэн 2020
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  3. 3
    Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells

    Receptor ligand-triggered resistance to alectinib and its circumvention by Hsp90 inhibition in EML4-ALK lung cancer cells -н Azusa Tanimoto, Tadaaki Yamada, Shigeki Nanjo, Shinji Takeuchi, Hiromichi Ebi, Kenji Kita, Kunio Matsumoto, Seiji Yano

    Хэвлэсэн 2014
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  4. 4
    Japanese Society of Medical Oncology Clinical Guidelines: <i><scp>RAS</scp></i> (<i><scp>KRAS</scp>/<scp>NRAS</scp></i>) mutation testing in colorectal cancer patients

    Japanese Society of Medical Oncology Clinical Guidelines: <i><scp>RAS</scp></i> (<i><scp>KRAS</scp>/<scp>NRAS</scp></i>) mutation testing in colorectal cancer patients -н Hiroya Taniguchi, Kentaro Yamazaki, Takayuki Yoshino, Kei Muro, Yasushi Yatabe, Toshiaki Watanabe, Hiromichi Ebi, Atsushi Ochiai, Eishi Baba, Katsuya Tsuchihara

    Хэвлэсэн 2015
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  5. 5
    High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with <i>EGFR</i>-mutant lung cancer cells

    High efficacy of third generation EGFR inhibitor AZD9291 in a leptomeningeal carcinomatosis model with <i>EGFR</i>-mutant lung cancer cells -н Shigeki Nanjo, Hiromichi Ebi, Sachiko Arai, Shinji Takeuchi, Tadaaki Yamada, Satsuki Mochizuki, Yasunori Okada, Mitsutoshi Nakada, Takashi Murakami, Seiji Yano

    Хэвлэсэн 2015
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  6. 6
    Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors

    Phase I and pharmacokinetic study of sorafenib, an oral multikinase inhibitor, in Japanese patients with advanced refractory solid tumors -н Hironobu Minami, Kenji Kawada, Hiromichi Ebi, Koichi Kitagawa, Yon‐il Kim, Kazuhiro Araki, Hirofumi Mukai, Makoto Tahara, Hikaru Nakajima, Keiko Nakajima

    Хэвлэсэн 2008
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  7. 7
    EGFR-TKI Resistance Due to <i>BIM</i> Polymorphism Can Be Circumvented in Combination with HDAC Inhibition

    EGFR-TKI Resistance Due to <i>BIM</i> Polymorphism Can Be Circumvented in Combination with HDAC Inhibition -н Takayuki Nakagawa, Shinji Takeuchi, Tadaaki Yamada, Hiromichi Ebi, Takako Sano, Shigeki Nanjo, Daisuke Ishikawa, Mitsuo Sato, Yoshinori Hasegawa, Yoshitaka Sekido, Seiji Yano

    Хэвлэсэн 2013
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  8. 8
    Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in <i>KRAS</i>-Mutant Lung Cancer

    Epithelial-to-Mesenchymal Transition Defines Feedback Activation of Receptor Tyrosine Kinase Signaling Induced by MEK Inhibition in <i>KRAS</i>-Mutant Lung Cancer -н Hidenori Kitai, Hiromichi Ebi, Shuta Tomida, Konstantinos V. Floros, Hiroshi Kotani, Yuta Adachi, Satoshi Oizumi, Masaharu Nishimura, Anthony C. Faber, Seiji Yano

    Хэвлэсэн 2016
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  9. 9
    Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK

    Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK -н Ryohei Katayama, Tahsin M. Khan, Cyril H. Benes, Eugene Lifshits, Hiromichi Ebi, Victor M. Rivera, William C. Shakespeare, A. John Iafrate, Jeffrey A. Engelman, Alice T. Shaw

    Хэвлэсэн 2011
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  10. 10
    First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities

    First-Line Genomic Profiling in Previously Untreated Advanced Solid Tumors for Identification of Targeted Therapy Opportunities -н Junichi Matsubara, Kumi Mukai, Tomohiro Kondo, Masahiro Yoshioka, Hidenori Kage, Katsutoshi Oda, Ryo Kudo, Sadakatsu Ikeda, Hiromichi Ebi, Kei Muro, Ryuji Hayashi, Nahomi Tokudome, Nobuyuki Yamamoto, Manabu Muto

    Хэвлэсэн 2023
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  11. 11
    PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1

    PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1 -н Hiromichi Ebi, Carlotta Costa, Anthony C. Faber, Madhuri Nishtala, Hiroshi Kotani, Dejan Juric, Patricia Della Pelle, Youngchul Song, Seiji Yano, Mari Mino‐Kenudson, Cyril H. Benes, Jeffrey A. Engelman

    Хэвлэсэн 2013
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  12. 12
    A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors

    A Phase I Dose-Escalation Study of ZD6474 in Japanese Patients with Solid, Malignant Tumors -н Tomohide Tamura, Hironobu Minami, Yasuhide Yamada, Noboru Yamamoto, Tatsu Shimoyama, Haruyasu Murakami, Atsushi Horiike, Yasuhito Fujisaka, Tetsu Shinkai, Makoto Tahara, Kenji Kawada, Hiromichi Ebi, Yasutsuna Sasaki, Haiyi Jiang, Nagahiro Saijo

    Хэвлэсэн 2006
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  13. 13
    Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET

    Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET -н Lu Xu, Eiki Kikuchi, Chunxiao Xu, Hiromichi Ebi, Dalia Ercan, Katherine A. Cheng, Robert F. Padera, Jeffrey A. Engelman, Pasi A. Jänne, Geoffrey I. Shapiro, Takeshi Shimamura, Kwok‐Kin Wong

    Хэвлэсэн 2012
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  14. 14
    Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers

    Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers -н Hiromichi Ebi, Ryan B. Corcoran, Anurag Singh, Zhao Chen, Youngchul Song, Eugene Lifshits, David P. Ryan, Jeffrey A. Meyerhardt, Cyril H. Benes, Jeffrey Settleman, Kwok‐Kin Wong, Lewis C. Cantley, Jeffrey A. Engelman

    Хэвлэсэн 2011
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  15. 15
    TGF-β-dependent reprogramming of amino acid metabolism induces epithelial–mesenchymal transition in non-small cell lung cancers

    TGF-β-dependent reprogramming of amino acid metabolism induces epithelial–mesenchymal transition in non-small cell lung cancers -н Fumie Nakasuka, Sho Tabata, Takeharu Sakamoto, Akiyoshi Hirayama, Hiromichi Ebi, Tadaaki Yamada, Ko Umetsu, Maki Ohishi, Ayano Ueno, Hisatsugu Goto, Masahiro Sugimoto, Yasuhiko Nishioka, Yasuhiro Yamada, Masaru Tomita, Atsuo T. Sasaki, Seiji Yano, Tomoyoshi Soga

    Хэвлэсэн 2021
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  16. 16
    CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer

    CIRCULATE‐Japan: Circulating tumor DNA–guided adaptive platform trials to refine adjuvant therapy for colorectal cancer -н Hiroya Taniguchi, Yoshiaki Nakamura, Daisuke Kotani, Hiroki Yukami, Saori Mishima, Kentaro Sawada, Hiromichi Shirasu, Hiromichi Ebi, Takeharu Yamanaka, Alexey Aleshin, Paul R. Billings, Matthew Rabinowitz, Eiji Oki, Ichiro Takemasa, Takeshi Kato, Masaki Mori, Takayuki Yoshino

    Хэвлэсэн 2021
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  17. 17
    Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer

    Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer -н Carlotta Costa, Hiromichi Ebi, Miriam Martini, Sean A. Beausoleil, Anthony C. Faber, Charles T. Jakubik, Alan Huang, Youzhen Wang, Madhuri Nishtala, Ben A. Hall, Klarisa Rikova, Jean J. Zhao, Emilio Hirsch, Cyril H. Benes, Jeffrey A. Engelman

    Хэвлэсэн 2014
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  18. 18
    Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer

    Response to Anti-EGFR Therapy in Patients with BRAF non-V600–Mutant Metastatic Colorectal Cancer -н Rona Yaeger, Daisuke Kotani, Sebastián Mondaca, Aparna R. Parikh, Hideaki Bando, Emily E. Van Seventer, Hiroya Taniguchi, HuiYong Zhao, Claire N. Thant, Elisa de Stanchina, Neal Rosen, Ryan B. Corcoran, Takayuki Yoshino, Zhan Yao, Hiromichi Ebi

    Хэвлэсэн 2019
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  19. 19
    EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i>-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib

    EGFR-Mediated Reactivation of MAPK Signaling Contributes to Insensitivity of <i>BRAF</i>-Mutant Colorectal Cancers to RAF Inhibition with Vemurafenib -н Ryan B. Corcoran, Hiromichi Ebi, Alexa B. Turke, Erin M. Coffee, Michiya Nishino, Alexandria P. Cogdill, Ronald D. Brown, Patricia Della Pelle, Dora Dias‐Santagata, Kenneth E. Hung, Keith T. Flaherty, Adriano Piris, Jennifer A. Wargo, Jeffrey Settleman, Mari Mino‐Kenudson, Jeffrey A. Engelman

    Хэвлэсэн 2012
    Бүрэн текст авах Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:
  20. 20
    Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer

    Combined inhibition of KRASG12C and mTORC1 kinase is synergistic in non-small cell lung cancer -н Hidenori Kitai, Philip H. Choi, Yu Chi Yang, Jacob A. Boyer, Adele Whaley, Priya Pancholi, Claire N. Thant, Jason Reiter, Kevin Chen, Vladimir Markov, Hirokazu Taniguchi, Rui Yamaguchi, Hiromichi Ebi, James Evans, Jingjing Jiang, Bianca J. Lee, David Wildes, Elisa de Stanchina, Jacqueline A.M. Smith, Mallika Singh, Neal Rosen

    Хэвлэсэн 2024
    Бүрэн текст авах
    Artigo
    Жагсаалт руу хадгалах
    -д хадгалсан:

Хайх хэрэгслүүд: